Repeated intravenous (IV) ketamine infusions significantly reduce symptom severity in individuals with chronic post-traumatic stress disorder (PTSD) and the improvement is rapid and maintained for several weeks afterwards, according to a study conducted by researchers from the Icahn School of Medicine at Mount Sinai. The study, published January 5 in the American Journal of Psychiatry, is the first randomized, controlled trial of repeated ketamine administration for chronic PTSD and suggests this may be a promising treatment for PTSD patients.
Mount Sinai sure isn’t wasting any time.
The real question is: what’s better for treating PTSD—MDMA, ketamine, or a different psychedelic drug altogether?